Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Liabilities and Shareholders Equity (2021 - 2026)

TriSalus Life Sciences has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $71.0 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 147.96% year-over-year to $71.0 million; the TTM value through Mar 2026 reached $184.1 million, up 63.63%, while the annual FY2025 figure was $35.3 million, 47.39% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $71.0 million at TriSalus Life Sciences, up from $35.3 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $251.3 million in Q3 2022 and troughed at $12.2 million in Q2 2023.
  • A 5-year average of $69.4 million and a median of $32.4 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 95.12% in 2023 and later skyrocketed 165.01% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $22.0 million in 2022, then grew by 11.83% to $24.6 million in 2023, then decreased by 2.55% to $24.0 million in 2024, then surged by 47.39% to $35.3 million in 2025, then soared by 100.9% to $71.0 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for TLSI at $71.0 million in Q1 2026, $35.3 million in Q4 2025, and $36.5 million in Q3 2025.